{"id":"W2495043549","doi":"10.1016/j.clbc.2016.07.008","title":"Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5","year":2016,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Trastuzumab; Docetaxel; Epirubicin; Breast cancer; Internal medicine; Oncology; Cyclophosphamide; Neoadjuvant therapy; Regimen; Ejection fraction; Chemotherapy; Cancer; Heart failure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001186686,0.0009535867,0.001449836,0.0006636379,0.0003357641,0.0007724719,0.0007078245,0.0008781612,0.003405746],"category_scores_gemma":[0.0007480272,0.0004424285,0.0006675085,0.000592193,0.0006835646,0.0007811241,0.0003136514,0.002021332,0.0005482526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009007951,"about_ca_system_score_gemma":0.001491234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002407626,"about_ca_topic_score_gemma":0.009878078,"domain_scores_codex":[0.9994915,0.0002379954,0.00002374819,0.00008651856,0.00003936464,0.0001210097],"domain_scores_gemma":[0.9996537,0.00005845504,0.00004993501,0.0000303196,0.00001297208,0.0001946299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7493042,0.04990271,0.004364059,0.0005089906,0.001288829,0.0001672425,0.0001580355,0.002768927,0.0226187,0.0007370579,0.002902544,0.1652787],"study_design_scores_gemma":[0.538483,0.4277587,0.01471537,0.00008144259,0.0006747985,0.0003343223,0.00007356328,0.001507334,0.00965751,0.0003205016,0.006350176,0.00004332918],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913254,0.002993363,0.0004252005,0.000381392,0.000178672,0.001158464,0.0004335009,0.00006704994,0.003036868],"genre_scores_gemma":[0.9901484,0.002137141,0.001301473,0.0004737276,0.00009682561,0.0008934578,0.001067181,0.00002131495,0.003860743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003405746,"threshold_uncertainty_score":0.01139337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02857434050699278,"score_gpt":0.3893923807055655,"score_spread":0.3608180401985728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}